An influential Food and Drug Administration advisory committee on Friday said the agency should authorize boosters of Johnson & Johnson’s single-shot Covid-19 vaccine to the more than 15 million Americans who have already received the initial dose.
The unanimous vote – by the agency’s Vaccines and Related Biological Products Advisory Committee – is a critical step before the U.S. can begin giving second shots to J&J recipients, some of whom have said they are anxious to get the additional protection.
The panel recommended the boosters to everyone 18 and over who’s already received J&J’s first shot at least two months after the initial dose. Many committee members said it should be considered a two-dose vaccine much like Moderna and Pfizer’s.
Read the full article.
JUST IN: An advisory panel has unanimously recommended that the FDA authorize a J&J booster dose for people 18 years and older at least 2 months after their initial one-shot immunization.https://t.co/lNXoERueM7
— NPR (@NPR) October 15, 2021